StreetInsider.com News Articles

H.C. Wainwright Reiterates Neutral Rating on Traws Pharma Inc. (TRAW)

Tue, 18 Aug 2026 06:46:24 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Neutral rating and $1.00 price target on Traws Pharma Inc. (NASDAQ: TRAW).

The analyst commented: "TRAW’s 2Q26 update provides a clearer route back toward a clinical catalyst for TXM, but we do not believe enough has changed to move us off our Neutral rating and $1 price target. Following more detailed MHRA feedback, TRAW expects to resubmit an updated toxicology package by the end of 3Q26, with the agency previously indicating a formal response is expected within 30 days of resubmission; the company is also targeting resolution of the U.S. clinical hold by year-end.

Traws Pharma (TRAW) Tops Q2 EPS by 27c

Mon, 17 Aug 2026 06:35:33 -0400

Traws Pharma (NASDAQ: TRAW) reported Q2 EPS of ($0.16), $0.27 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Traws Pharma (TRAW) click here.

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26933306.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26933306.html

Form 10-Q Traws Pharma, Inc. For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931840.html

Form 10-Q Traws Pharma, Inc. For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931840.html

Form 8-K Traws Pharma, Inc. For: Aug 14

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931593.html

Form 8-K Traws Pharma, Inc. For: Aug 14

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931593.html

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Fri, 14 Aug 2026 16:30:00 -0400

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study
Completed the April 2026 private placement and received shareholder approval of the Series B and Series C tranches, enabling access to up to $50 million in potential additional financing, subject to achievement of program milestones and investor participation

NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Fri, 14 Aug 2026 16:30:00 -0400

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study
Completed the April 2026 private placement and received shareholder approval of the Series B and Series C tranches, enabling access to up to $50 million in potential additional financing, subject to achievement of program milestones and investor participation

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 13:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26928360.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Squadron Capital Management LLC

Fri, 14 Aug 2026 13:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26928360.html

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26925253.html

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26925253.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911195.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911195.html

Form 8-K Traws Pharma, Inc. For: Jul 29

Fri, 31 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260731/26850927.html

Form 8-K Traws Pharma, Inc. For: Jul 29

Fri, 31 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260731/26850927.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: Pauza Charles David

Thu, 16 Jul 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260716/26778654.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: Pauza Charles David

Thu, 16 Jul 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260716/26778654.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: CAUTREELS WERNER

Wed, 15 Jul 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26775283.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: CAUTREELS WERNER

Wed, 15 Jul 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26775283.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: Savchuk Nikolay

Wed, 15 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260715/26774559.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: Savchuk Nikolay

Wed, 15 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260715/26774559.html

Form 4 Traws Pharma, Inc. For: Jul 09 Filed by: STOVER JACK E

Tue, 14 Jul 2026 21:57:00 -0400

si-local-file:///var/storage/secattach/20260714/26769509.html